A management report from Tufts CSDD, based on an executive roundtable, found that drug companies and their development partners are incorporating business planning earlier in clinical development
A management report from Tufts CSDD, based on an executive roundtable, found that drug companies and their development partners are incorporating business planning earlier in clinical development, as well other strategies, to help increase the clinical success rate of new drug candidates. The roundtable also discussed how using a more rigorous use of risk-adjusted net present value calculations earlier in clinical development can improve decision making on how to structure clinical trials.
